Amyloid MS service
For the rapid detection of Alzheimer's Disease in blood
Dedicated to Drug Discovery and Development
Innovation
Shimadzu recently developed the Amyloid Mass Spectrometry (MS) Service — a new simple, low-cost blood test for early screening of amyloid-positive subjects. This method enables early and accurate detection of amyloid deposition in the brain with an easy-to-acquire blood sample.
Unlike conventional methods, Shimadzu’s new test is minimally invasive, cost-effective and suitable for large-scale deployment.
For Research Use Only. Not for use in diagnostic procedures. Amyloid MS Service is for drug discovery and development only.
E-Book Amyloid MS service
Poster #47112: MALDI-TOF IP-MS quantification of plasma amyloid peptides in Alzheimer’s disease
Poster #39194: Identification of ADAMTS4 as an APP-cleaving enzyme at 669 site in APP669-711 production pathway
Poster #45810: Studies on the Pragmatic Performance and Validity of a Plasma Amyloid β Measurement System by Immunoprecipitation-Mass Spectrometry
Poster # 45884: Plasma Aβ biomarker associated with cognitive decline in preclinical Alzheimer’s disease
Other Posters (from AAIC2019 and AAIC2018):
1I Immunoprecipitation-mass spectrometry (IP-MS) for plasma amyloid-β can be conducted with several kinds of monoclonal antibodies
2I Analysis of the amyloid β-related peptides in mouse plasma and cell culture media
3I Mass Spectrometric Quantification of Tau Protein Isoforms in Human Cerebrospinal Fluid
4I Immunoassay for Plasma APP669-711‚ One Component of the Amyloid β Biomarker
Request for service Amyloid MS
RUO only / in collaboration with our Clinical Partners
Technology and benefits
These new blood-based biomarkers were discovered in 2014 by Shimadzu Corporation and the Japanese National Center for Geriatrics and Gerontology (NCGG). It is based on immunoprecipitation followed by MALDI-TOF analysis. Its benefits are:
- Reduced costs per test
- A less invasive blood-based sampling technique
- Low sample volume requirements (0.5 mL)
Collaboration with University Hospital Montpellier
Shimadzu, one of the world leaders in analytical instrumentation, introduces the collaboration with the Clinical Laboratory and Proteomics Platform of the CHU University Hospital of Montpellier, France. With the team of professors Sylvain Lehmann and Christophe Hirtz, they focus on MS (mass spectrometry) based blood amyloid-beta analysis for early screening of amyloid-positive subjects.
